Cocrystal Pharma completes enrollment of 78 subjects in Phase 2a study of CC-42344 for influenza A

Cocrystal Pharma, Inc.

Enrolled 78 healthy subjects in randomized, double-blind, placebo-controlled Phase 2a human challenge study of oral PB2 inhibitor CC-42344.
Study evaluating safety, tolerability, antiviral and clinical measurements of CC-42344 for pandemic and seasonal influenza A.
Topline results expected later this year; study conducted in the United Kingdom.
Company also plans to begin Phase 1 study in Australia with inhaled formulation of CC-42344.
Received positive Pre-IND feedback from FDA in March 2024 guiding Phase 2b protocol.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.